Jasper Therapeutics Quote - JSPRW | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Jasper Therapeutics Inc (JSPRW) Share Price

Jasper Therapeutics Inc (JSPRW)

0.222

0.00

(0.00%)

Closed 24 November 8:00AM

Delayed by 15 minutes

0.222

0.00

(0.00%)

After Hours: 8:00AM

Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Current Price

0.222

Bid

0.0003

Offer

0.30

Volume

251

0.202 Day's Range 0.222

0.0351 52 Week Range 0.3818

Market Cap

Previous Close

0.222

Open

0.202

Last Trade

Last Trade Time

Financial Volume

US$ 51

VWAP

0.202

Average Volume (3m)

5,234

Shares Outstanding

15,001,353

Dividend Yield

-

PE Ratio

-5.13

Earnings Per Share (EPS)

-4.3

Revenue

-

Net Profit

-64.47M

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem ce... Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.jaspertherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

-

Jasper Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker JSPRW. The last closing price for Jasper Therapeutics was US$0.22. Over the last year, Jasper Therapeutics shares have traded in a share price range of US$ 0.0351 to US$ 0.3818.

Jasper Therapeutics currently has 15,001,353 shares in issue. The market capitalisation of Jasper Therapeutics is US$3.33 million. Jasper Therapeutics has a price to earnings ratio (PE ratio) of -5.13.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.036001	19.3554804058	0.185999	0.222	0.16	1973	0.20238662	CS
4	0.0312	16.3522012579	0.1908	0.2526	0.090966	3357	0.20593393	CS
12	0.00517	2.38435640825	0.21683	0.2526	0.090966	5234	0.20101273	CS
26	0.077	53.1034482759	0.145	0.2526	0.090966	3894	0.20362955	CS
52	0.1423	178.544542033	0.0797	0.3818	0.0351	13089	0.15989778	CS
156	-1.118	-83.4328358209	1.34	1.7	0.016	17667	0.17109345	CS
260	-1.508	-87.1676300578	1.73	2.24	0.016	21516	0.51255198	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PDYNPalladyne AI Corporation	US$ 4.59 (129.50%)	83.07M
QMCOQuantum Corporation	US$ 9.11 (126.62%)	39.48M
NANano Labs Ltd	US$ 8.26 (89.02%)	2.03M
XCURExicure Inc	US$ 18.60 (71.27%)	4.59M
SKKSKK Holdings Limited	US$ 1.75 (59.09%)	107.47M
AMIXAutonomix Medical Inc	US$ 6.21 (-54.07%)	946.09k
CETXCemtrex Inc	US$ 0.1146 (-41.74%)	24.39M
MSWMing Shing Group Holdings Ltd	5.90 (-35.52%)	417.08k
RMSGReal Messenger Corporation	US$ 3.09 (-26.25%)	313.51k
ENSCEnsysce Biosciences Inc	US$ 0.4414 (-25.49%)	4M
ELABElevai Labs Inc	US$ 0.0201 (-0.50%)	425.38M
NVDANVIDIA Corporation	US$ 141.95 (-3.22%)	236.51M
SMCISuper Micro Computer Inc	US$ 33.15 (11.62%)	159.61M
VRPXVirpax Pharmaceuticals Inc	US$ 0.5501 (-6.72%)	159.39M
SOUNSoundHound AI Inc	US$ 8.24 (18.05%)	107.91M

RG51

RG51 56 seconds ago

I'm in exactly the same boat, ignorance is bliss lol

SunshineSmiles

SunshineSmiles 1 minute ago

MONI MC Hammer Time .10 cents

IndexR

Stinger2014

Stinger2014 1 minute ago

DIVI I believe was just noise. I guess we will see. Have a great weekend!!

Konaploinks

Konaploinks 2 minutes ago

Join us on Tuesday, December 3, 2024, at 10:00 am PT for a live webinar “IonQ’s Full-Stack Quantum Innovation.” Register today as spots are limited.
Register
IonQ Leadership
OUR MISSION:
To build the world’s best quantum computers to solve the world’s most complex problem

Watts Watt

Watts Watt 2 minutes ago

Sumpkins rotten in DENMARK

glenn1919

glenn1919 2 minutes ago

DOUG.......DEVS............................https://stockcharts.com/h-sc/ui?s=DOUG&p=D&yr=0&mn=2&dy=12&id=p84071410134

wadegarret

wadegarret 3 minutes ago

HALO- I still think the sell off was an over reaction

While I understand that investors didn't like the deal to buy Evotech, as it would take 2 years to see a accretiveness in earnings, I still think the sell off has been a over reaction. I mean investors had to know about the p

WeTheMarket

WeTheMarket 3 minutes ago

Mick, great call, warrants up 70% yesterday on above average volume, up another 17% after market close.

mascale

mascale 3 minutes ago

The 4th Thursday in November is mostly a workday, worldwide.

Konaploinks

Konaploinks 5 minutes ago

Company Overview

The dawn of the quantum age is here. IonQ is developing quantum computers designed to solve the world’s most complex problems, and transform business, society and the planet for the better.

Founded on more than 25 years of pioneering academic research,

JTORENCE

JTORENCE 5 minutes ago

Guzzi62 AMEN TO THAT. " Please, can someone BO this at 10-15 billion, preferable before Christmas"

dstock07734

dstock07734 6 minutes ago

No BO since no BP can afford it. I don't guess and I don't bet. That's why I can be all in.

MysticMaestro69

MysticMaestro69 7 minutes ago

How do I find the outcome of the Nov 22 vote deadline?

glenn1919

glenn1919 7 minutes ago

HYLN...............................https://stockcharts.com/h-sc/ui?s=HYLN&p=W&b=5&g=0&id=p86431144783

weedtrader420

weedtrader420 7 minutes ago

BUYING BUYING BUYING Loaded up One zero coming off

jammy32

jammy32 8 minutes ago

You do realize it’s the end of November ?????

nowwhat2

nowwhat2 8 minutes ago

Conservative financial liberalism
"Just let us do what frickin' ever we want !......Don't DICTATE to us your financial system !"

Liberal frickin' liberalism
"Just let us do what frickin' ever we want !......Don't DICTATE to us your moral system !"

Capital

weedtrader420

weedtrader420 8 minutes ago

☝️🤑☝️📈🚀

ChannelTrader

ChannelTrader 9 minutes ago

ICE Buffalo official takes shot at NY Gov Hochul after arrest of wanted illegal immigrant

https://www.foxnews.com/politics/ice-buffalo-official-takes-shot-ny-governor-hochul-after-arrest-wanted-illegal-immigrant

glenn1919

glenn1919 9 minutes ago

BBAI...................................https://stockcharts.com/h-sc/ui?s=BBAI&p=W&b=5&g=0&id=p86431144783

trunkmonk

trunkmonk 14 minutes ago

ask for the Moon, accept what they have stolen.

The ELTP King

The ELTP King 14 minutes ago

Sh*t just got REAL.

Oct. 29, 2024
Protega Pharmaceuticals Receives FDA Approval for ROXYBOND™ (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
https://www.prnewswire.com/news-releases/protega-pharmac

glenn1919

glenn1919 15 minutes ago

ZVIA...................................https://stockcharts.com/h-sc/ui?s=ZVIA&p=W&b=5&g=0&id=p86431144783

wadegarret

wadegarret 15 minutes ago

R59- SMCI

I felt the same when it was $18. I mean when an auditor of a major company quits, it usually means something pretty negative. I've been burnt many times trying to time a bottom for stocks that had bad news. Thing is, if SMCI really has no bad stuff going on, then even at

Stinger2014

Stinger2014 15 minutes ago

Here’s to good news! Let’s check all the boxs

Jasper Therapeutics

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions